Genmab A/S (NASDAQ:GMAB) Stock Position Reduced by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC cut its stake in shares of Genmab A/S (NASDAQ:GMAB) by 19.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,121 shares of the company’s stock after selling 8,858 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Genmab A/S were worth $754,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Two Sigma Advisers LP grew its position in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after acquiring an additional 280,900 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Genmab A/S in the second quarter worth approximately $1,354,000. Natixis Advisors LLC grew its position in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after acquiring an additional 47,437 shares in the last quarter. Finally, FMR LLC grew its position in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $20.80 on Friday. The stock has a market cap of $13.76 billion, a P/E ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company has a fifty day moving average price of $21.19 and a 200 day moving average price of $24.10.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the previous year, the company earned $0.47 earnings per share. As a group, equities research analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.